Linked Life Data

10155271

Source:http://linkedlifedata.com/resource/pubmed/id/10155271

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1995-11-22
pubmed:abstractText
Per capita expenditure on pharmaceuticals is higher in Japan than in the US, despite a series of drug price reductions instigated by the Japanese Ministry of Health and Welfare that began in 1981. For some individual products, these price reductions cumulatively totalled more than 50%. This article argues that although the price of individual drugs is lower in Japan than in the US, aggregate expenditure is higher because of the greater use of newly-introduced original drugs and lower use of generics. Providers and consumers also tend to use drugs in larger quantities in Japan, because of polypharmacy and greater use of vitamins and nutrients, antihypertensives, cerebral metabolic activators (e.g. idebenone) and milder-acting drugs (i.e. drugs with low toxicity but unproven clinical efficacy). The level of expenditure is unlikely to decline, despite changes to pricing policy and ongoing efforts to improve the pharmaceutical distribution system and to discourage physician dispensing activities.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
T
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1170-7690
pubmed:author
pubmed:issnType
Print
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
424-33
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed:year
1994
pubmed:articleTitle
Pharmaceutical prices, quantities and innovation. Comparing Japan with the US.
pubmed:affiliation
Faculty of Policy Management, School of Medicine, Keio University, Tokyo, Japan.
pubmed:publicationType
Journal Article, Comparative Study, Review